Avenue Capital Group
Avenue Capital Group, established in 1995 by Marc Lasry and Sonia E. Gardner, is a New York City-based investment firm specializing in distressed debt and special situation investments across the United States, Europe, and Asia. The firm is recognized for its expertise in investing in the public and private debt and equity securities of distressed companies across various industries, as well as its focus on the real estate sector and securitized loan obligations. Avenue Capital Group provides a range of debt facilities, including loans, revolving credit lines, second lien, secured debt, mezzanine financing, senior debt, and bonds, catering to small and medium-sized companies for purposes such as bankruptcy, buyouts, initial public offerings, and growth initiatives. With a workforce of approximately 300 employees, Avenue Capital leverages the extensive experience of its founders, who have dedicated their careers to distressed investments.
Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.
Ocugen, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to discovering, developing, and commercializing innovative therapies aimed at curing blinding diseases. The company's pipeline includes several promising product candidates, such as OCU200, a novel fusion protein in preclinical development for treating wet age-related macular degeneration (AMD), diabetic retinopathy, and diabetic macular edema. Additionally, Ocugen is developing OCU400 for retinitis pigmentosa, a rare genetic disorder, and OCU410 for dry AMD. The company utilizes its Modifier Gene Therapy Platform to address unmet medical needs in the field of retinal diseases, including inherited conditions and multifactorial diseases. Ocugen has also established a strategic partnership with CanSino Biologics Inc. for the co-development and manufacturing of gene therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.